Last updated: August 1, 2026
Hydroflumethiazide is an obsolete thiazide diuretic with no identifiable active clinical-development program, no meaningful current commercial market, and no material patent-based exclusivity. Its historical use was concentrated in hypertension and edema. Current treatment has shifted to hydrochlorothiazide, chlorthalidone, indapamide, loop diuretics, and newer antihypertensive combinations. A commercial relaunch would face limited clinical differentiation, generic competition, low pricing, and regulatory requirements for renewed approval.
What is hydroflumethiazide used for?
Hydroflumethiazide is a benzothiadiazine diuretic that increases renal excretion of sodium and water by inhibiting sodium-chloride reabsorption in the distal convoluted tubule. It was historically used for:
- Hypertension
- Edema associated with congestive heart failure
- Hepatic cirrhosis
- Renal disorders
- Edema associated with corticosteroid or estrogen therapy
Hydroflumethiazide was marketed in the United States under the brand name Diucardin. Historical labeling described oral tablets in multiple strengths, including 25 mg and 50 mg formulations. The product is no longer a significant component of routine U.S. hypertension treatment.
Thiazide and thiazide-like diuretics remain clinically relevant, but hydroflumethiazide has been displaced by drugs with stronger guideline support, broader generic availability, or more favorable dosing and evidence profiles. Hydrochlorothiazide is widely used in fixed-dose combinations. Chlorthalidone and indapamide are often preferred when longer duration of action is clinically important.
What is the current clinical trial status of hydroflumethiazide?
No active interventional clinical-development program for hydroflumethiazide is apparent in major public clinical-trial databases. ClinicalTrials.gov contains extensive studies of thiazide diuretics and hypertension, but hydroflumethiazide is not a current development-stage asset comparable to hydrochlorothiazide, chlorthalidone, indapamide, or investigational antihypertensive agents (ClinicalTrials.gov, n.d.).
| Development category |
Hydroflumethiazide status |
| Active Phase 1 trials |
None identified |
| Active Phase 2 trials |
None identified |
| Active Phase 3 trials |
None identified |
| Registration-enabling studies |
None identified |
| Active pivotal hypertension program |
None identified |
| Current biosimilar program |
Not applicable |
| Current branded development |
None identified |
| Current combination-product development |
None identified |
The absence of a current trial program is consistent with hydroflumethiazide’s age, established mechanism, and lack of commercial differentiation. Any sponsor seeking a new U.S. approval would likely need to address current FDA requirements for product quality, bioequivalence where applicable, labeling, manufacturing controls, and clinical evidence supporting the proposed indication.
Does hydroflumethiazide have FDA approval today?
Hydroflumethiazide has historical FDA approval and historical U.S. marketing status, but it is not a current growth product in the FDA market. The principal branded product, Diucardin, is generally treated as discontinued rather than actively marketed.
FDA product databases distinguish between approved products that remain marketed and products that have been discontinued. A discontinued product is not automatically equivalent to a withdrawn approval for safety or efficacy reasons. That distinction matters for regulatory strategy. A sponsor seeking to reintroduce hydroflumethiazide would need to determine whether any prior approval remains legally usable, whether the relevant application has been withdrawn, and whether the proposed product could qualify for an abbreviated pathway.
Hydroflumethiazide is not a biologic and therefore does not create biosimilar exposure. Its regulatory pathway would involve a conventional small-molecule drug application or an abbreviated application if an appropriate reference product and regulatory basis were available.
When does hydroflumethiazide lose exclusivity?
Hydroflumethiazide’s meaningful patent and regulatory exclusivity expired decades ago.
The compound was discovered and commercialized before the modern U.S. patent-term system. Any composition-of-matter, formulation, or early use patents associated with historical products would have expired long before the current market period. No active patent estate is known to provide market exclusivity for hydroflumethiazide in the United States.
| Exclusivity category |
Current position |
| Original composition patent |
Expired |
| Historical formulation patents |
Expired |
| Historical method-of-use patents |
Expired |
| Regulatory exclusivity |
Expired |
| Orange Book patent protection |
No commercially relevant active protection identified |
| Pediatric exclusivity |
None identified |
| Orphan-drug exclusivity |
None identified |
| Biosimilar reference-product exclusivity |
Not applicable |
The molecule’s commercial risk is therefore generic competition rather than patent litigation. A new product could potentially obtain protection for a novel formulation, delivery system, combination, or manufacturing process, but such claims would need to satisfy novelty, non-obviousness, enablement, and written-description requirements.
What patents protect hydroflumethiazide?
No unexpired, commercially material U.S. patent estate has been identified for hydroflumethiazide as an active pharmaceutical ingredient.
Historical intellectual-property coverage likely included the compound itself and conventional pharmaceutical compositions. Those rights are no longer available to block generic production. New patent filings could theoretically cover:
- Modified-release hydroflumethiazide
- Fixed-dose combinations with renin-angiotensin system inhibitors
- Low-dose products designed to reduce electrolyte abnormalities
- Specific crystalline or amorphous forms
- Improved dissolution or stability systems
- Novel manufacturing routes
- Combination therapy for resistant hypertension
- Patient-selection or dosing methods
These opportunities would have limited blocking power unless the formulation or method generated a clinically meaningful advantage. A formulation patent covering a narrow dosage form would not necessarily prevent manufacture of conventional hydroflumethiazide tablets.
What is the Orange Book status of hydroflumethiazide?
Hydroflumethiazide does not have a meaningful current Orange Book position comparable to actively marketed branded drugs with listed patents and pending Paragraph IV disputes.
The Orange Book is relevant only when an approved drug product has active marketing and listed patent information. For hydroflumethiazide, the historical product has no apparent active patent-based exclusivity that would support a current branded-generic litigation strategy (U.S. Food and Drug Administration, n.d.-a).
A future sponsor would need to establish the regulatory reference product, determine whether an ANDA pathway is available, and evaluate whether any new patents could be listed under FDA rules. Method-of-use patents would have limited practical effect if the relevant indication could be carved out of generic labeling.
Are there Paragraph IV challenges to hydroflumethiazide?
No current, commercially significant Paragraph IV litigation involving hydroflumethiazide has been identified.
Paragraph IV litigation is generally initiated when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. Because hydroflumethiazide lacks an active branded patent estate and is not a major current product, there is little basis for a conventional Paragraph IV dispute.
A future abbreviated-application strategy could face regulatory, pharmaceutical-equivalence, or reference-product issues rather than patent barriers. Litigation risk would increase only if a sponsor introduced a new protected formulation or combination and obtained approved patent listings.
What formulations are protected by hydroflumethiazide patents?
No current commercially relevant formulation patent has been identified.
Historical hydroflumethiazide products were conventional oral tablets. The absence of an active formulation estate leaves potential room for product differentiation, but it also removes the principal economic reason for premium pricing. Possible development concepts include extended-release tablets, combination tablets, and formulations designed to reduce hypokalemia or improve adherence.
The clinical and commercial value of those approaches would be difficult to establish. Hydrochlorothiazide combinations already provide broad treatment availability, while chlorthalidone and indapamide offer established alternatives for longer-acting thiazide therapy. A new hydroflumethiazide formulation would require evidence that it improves blood-pressure control, tolerability, adherence, or outcomes.
What is the market size and revenue outlook for hydroflumethiazide?
Hydroflumethiazide has no identifiable meaningful current branded-market revenue. Public market reports generally do not provide a standalone forecast category for the molecule, reflecting its limited commercial presence and lack of active branded promotion.
| Commercial factor |
Assessment |
| Current branded sales |
Negligible or unavailable |
| Current generic sales |
Limited and not separately visible in major market datasets |
| Price environment |
Low, generic-like |
| Prescriber demand |
Low |
| Hospital formulary position |
Limited |
| Reimbursement leverage |
Weak |
| Differentiation potential |
Low without a new formulation or combination |
| Five-year standalone revenue outlook |
Minimal under a conventional tablet strategy |
A simple market-entry projection illustrates the constraint:
| Scenario |
Product concept |
Commercial outlook |
| Base case |
Conventional generic tablet |
Low revenue; price competition dominates |
| Upside case |
Differentiated fixed-dose combination |
Modest niche opportunity if clinical value is demonstrated |
| Premium case |
Modified-release or tolerability-focused product |
Potentially higher pricing, but substantial development and reimbursement risk |
| Downside case |
Relaunch of historical brand without differentiation |
Unlikely to achieve durable adoption |
The relevant market is the broader diuretic and antihypertensive market, not hydroflumethiazide alone. That market includes low-cost generic hydrochlorothiazide, chlorthalidone, indapamide, spironolactone, and combination products. Hydroflumethiazide would compete against established supply chains, guideline familiarity, and fixed-dose combinations.
How does hydroflumethiazide compare with hydrochlorothiazide and chlorthalidone?
| Attribute |
Hydroflumethiazide |
Hydrochlorothiazide |
Chlorthalidone |
| Drug class |
Thiazide diuretic |
Thiazide diuretic |
Thiazide-like diuretic |
| Current market presence |
Minimal |
High |
Established |
| Fixed-dose combinations |
Limited historical use |
Extensive |
More limited |
| Guideline familiarity |
Low |
High |
High |
| Commercial pricing |
Generic-like |
Generic-like |
Generic-like |
| Patent barrier |
None of material value |
None for core molecule |
None for core molecule |
| Differentiation |
Low |
Broad combination availability |
Longer duration of action |
| Development attractiveness |
Low |
Low for new conventional products |
Low for new conventional products |
Hydrochlorothiazide has a stronger commercial position because it is embedded in numerous antihypertensive combinations. Chlorthalidone has a longer effective duration and remains an important comparator in hypertension management. Hydroflumethiazide lacks a clear pharmacologic or commercial advantage over either product.
What generic launch risks exist for hydroflumethiazide?
A generic launch would face limited patent risk but significant market-access risk. The main barriers would include:
- Confirming an acceptable FDA reference product and regulatory pathway.
- Demonstrating pharmaceutical equivalence and bioequivalence.
- Establishing reliable active-ingredient and finished-dose manufacturing.
- Securing distribution for a low-volume product.
- Obtaining formulary placement against established thiazide products.
- Managing low unit pricing and limited reimbursement upside.
- Demonstrating demand sufficient to support commercial manufacturing.
Manufacturing itself is unlikely to present a durable intellectual-property barrier. Thiazide production is established, and the relevant process patents would generally be expired. The greater risk is economic: low expected volume may not justify validation, regulatory filing, inventory, and pharmacovigilance costs.
What is the litigation and licensing outlook?
No material current litigation or licensing transaction involving hydroflumethiazide has been identified. There is no apparent active branded sponsor defending a patent estate, negotiating generic settlements, or licensing a proprietary delivery platform for the drug.
A licensing transaction would be more plausible for a broader cardiovascular combination or drug-delivery technology than for hydroflumethiazide alone. The asset’s value would depend on a new clinical claim, differentiated formulation, or inclusion in a combination product with commercial relevance.
Key Takeaways
- Hydroflumethiazide is a historical thiazide diuretic with minimal current commercial activity.
- No active clinical-trial program or modern drug-development strategy is apparent.
- Original composition, formulation, and use patents have expired.
- No meaningful current Orange Book patent position or Paragraph IV litigation has been identified.
- Biosimilar risk does not apply because hydroflumethiazide is a small-molecule drug.
- Conventional generic tablets would face low pricing and weak demand.
- A commercially viable relaunch would require a differentiated formulation, fixed-dose combination, or clinically supported tolerability advantage.
- Hydrochlorothiazide and chlorthalidone have stronger current market positions.
FAQs
Is hydroflumethiazide still prescribed for high blood pressure?
Hydroflumethiazide is rarely used in current practice. Hydrochlorothiazide, chlorthalidone, and indapamide have substantially stronger market and guideline positions.
Is hydroflumethiazide available as a generic drug?
Historical generic availability may exist in limited or discontinued channels, but hydroflumethiazide is not a significant widely marketed generic product in the United States.
Is hydroflumethiazide stronger than hydrochlorothiazide?
There is no current clinical-development evidence establishing a commercially meaningful superiority advantage. Hydrochlorothiazide has greater prescribing familiarity and much broader use in fixed-dose combinations.
Could a company relaunch Diucardin?
A relaunch would require regulatory, manufacturing, labeling, and commercial assessment. The historical brand name alone would not create market exclusivity, and a conventional relaunch would face weak differentiation.
Does hydroflumethiazide have renal or cardiovascular outcome data?
Historical diuretic studies support its pharmacologic use, but it does not have the current evidence base or market position of leading thiazide and thiazide-like comparators.
References
-
ClinicalTrials.gov. (n.d.). Search results for hydroflumethiazide. U.S. National Library of Medicine. https://clinicaltrials.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-over-counter-otc-monograph-order-requests
-
U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Center for Biotechnology Information. (n.d.). Hydroflumethiazide. PubChem compound summary. https://pubchem.ncbi.nlm.nih.gov/
-
National Library of Medicine. (n.d.). Hydroflumethiazide drug information. MedlinePlus and DailyMed resources. https://dailymed.nlm.nih.gov/
